Clinical trials: 18 Years and Over
COVID-19
Clinical Trial of SARS-CoV-2 mRNA Vaccine in China
This study is a phase I clinical trial. The investigators intent to evaluate the safety, tolerability and preliminary immunogenicity of SARS-CoV-2 mRNA vaccine (LVRNA009) in Chinese people aged 18 years and over.
- Trial name
- NCT05364047
- Testing
- Low-dose of LVRNA009, Middle-dose of LVRNA009, High-dose of LVRNA009
- Where
- 3 sites in China
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- AIM Vaccine Co., Ltd.
Tetanus
A Study to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over
This is a randomized, observer-blind, positive-controlled study. There will be 2 treatment groups, Subjects who gave informed consent and passed the questioning screen were randomly assigned 1:1 to be immunized with 1 dose of…
- Trial name
- NCT06123663
- Testing
- TTVA, TT
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Arthritis, Psoriatic
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor…
- Trial name
- IZAR-2 (NCT06641089)
- Testing
- Sonelokimab, Risankizumab
- Where
- 143 sites in United States, Bulgaria and 9 more
- Volunteers
- 600 people
- Sponsor
- MoonLake Immunotherapeutics AG
Pulmonary Arterial Hypertension
To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.
To demonstrate a dose response for 1 mg, 5 mg and 20 mg TID oral sildenafil for the treatment of subjects with PAH.
- Trial name
- NCT00430716
- Testing
- Sildenafil citrate
- Where
- 46 sites in United States, Belgium and 15 more
- Volunteers
- 130 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Breast Cancer
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called ARV-471) when given together with other medicines for the potential treatment of advanced or metastatic breast cancer.
- Trial name
- NCT05548127
- Testing
- ARV-471, Abemaciclib
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 37 people
- Sponsor
- Pfizer
Hypertension, Pulmonary
A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension
To evaluate the effect of three doses of oral sildenafil (20, 40 and 80 mg three times a day [TID]) on exercise capacity, as measured by the 6-Minute Walk test, as well as the safety and tolerability, after 12 weeks of treatment…
- Trial name
- NCT00644605
- Testing
- sildenafil
- Where
- 68 sites in United States, Australia and 21 more
- Volunteers
- 275 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Contraception
LCS16 vs. COC User Satisfaction and Tolerability Study
To evaluate user satisfaction in young nulliparous and parous women (18-29 years of age [inclusive]), using LCS16 compared to a COC over a period of 12 months.
- Trial name
- NCT03074045
- Testing
- Levonorgestrel (Kyleena, BAY86-5028), Ethinyl estradiol and drospirenone (Yarina, BAY86-5131)
- Where
- 9 sites in Russia
- Volunteers
- 145 people
- Sponsor
- Bayer
Breast Cancer
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called ARV-471) when given together with other medicines for the potential treatment of advanced or metastatic breast cancer.
- Trial name
- NCT05573555
- Testing
- ARV-471, Ribociclib
- Where
- 31 sites in United States, Canada and 2 more
- Volunteers
- 20 people
- Sponsor
- Pfizer
Breast Cancer
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: HR-positive…
- Trial name
- FourLight-3 (NCT06760637)
- Testing
- PF-07220060, letrozole, abemaciclib
- Where
- 460 sites in United States, Argentina and 28 more
- Volunteers
- 1,035 people
- Sponsor
- Pfizer
SARS-CoV-2
A Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in Chinese People
This is a cohort study to evaluate safety and immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in participants aged 18 years and over in China
- Trial name
- NCT05549206
- Testing
- SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose, SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine high dose
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- AIM Vaccine Co., Ltd.
SARS-CoV-2
A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China
This is a cohort study to evaluate safety and immunogenicity of COVID-19 mRNA Vaccine, Bivalent (LVRNA021) in participants aged 18 years and over in China
- Trial name
- NCT05547243
- Testing
- SARS-CoV-2 mRNA Vaccine, Bivalent Low dose, SARS-CoV-2 mRNA Vaccine, Bivalent High dose
- Where
- China
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- AIM Vaccine Co., Ltd.
Contraceptive, Oral, Hormonal
Cycle Control and Safety of E2-DRSP
The study will be performed as a multi-center, randomized, double-blind, parallel-group trial in fertile women aged between 18 and 35 years inclusive.
- Trial name
- NCT00653614
- Testing
- E2/DRSP (BAY 86-4891) dose 1 (SH T04984E), E2/DRSP (BAY 86-4891) dose 2 (80458739), E2/DRSP (BAY 86-4891) dose 3 (80458755)
- Where
- 25 sites in Germany
- Volunteers
- 635 people
- Sponsor
- Bayer
Tetanus
A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over
This is a randomized, observer-blind, positive-controlled study. There will be 2 treatment groups, Subjects who gave informed consent and passed the questioning screen were randomly assigned 1:1 to be immunized with 1 dose of…
- Trial name
- NCT06120751
- Testing
- TTVA, TT
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
COVID-19
Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of BBIBP-CorV
Study objectives: To evaluate the immunogenicity and immunity persistence and safety of recombinant novel coronavirus vaccine (CHO cells) after booster immunization in populations vaccinated with two doses of marketed novel…
- Trial name
- NCT05205083
- Testing
- Recombinant novel coronavirus vaccine (CHO cells)
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Contraception
FC Patch Low: Metabolism Study
The aim of the present study is to investigate the effects of the transdermal patch on the parameters of hemostasis (blood clotting), lipid (fat), and carbohydrate (sugars) metabolism in healthy women who require contraception.
- Trial name
- NCT00933179
- Testing
- Gestodene/EE Patch (BAY86-5016), EE/Levonorgestrel (Microgynon, BAY86-4977)
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bayer
Influenza
Reacto & Immunogenicity of TF Formulation of Influsplit SSW® 2002/03 v/s Std Formulation of Influsplit SSW® 2002/03
This is a comparative vaccination study of the reactogenicity and immunogenicity of a thiomersal-free formulation of Influsplit SSW® 2002/2003 versus the standard formulation of Influsplit SSW® 2002/2003 in individuals over 18…
- Trial name
- NCT00731029
- Testing
- Thiomersal free trivalent influenza split vaccine 2002/2003, GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2002/2003
- Where
- Germany
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Phase III, Open-Label, Single-Dose Study to Evaluate the Safety and Immunogenicity of Fluviral® Vaccine
Vaccination is currently the most effective means of controlling influenza and preventing its complications and mortality in persons at risk.
- Trial name
- NCT00505453
- Testing
- Fluviral®
- Where
- 2 sites in Canada
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults
The purpose of this trial is to describe the immunogenicity, the safety, and tolerability of FluLaval™ TR and Fluarix®, the latter serving as active comparator.
- Trial name
- NCT00380211
- Testing
- Influenza vaccine (A/H3N2, A/H1N1, and B strains), Fluarix
- Where
- 6 sites in United States
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years
This study is designed to test the safety and immunogenicity of Fluviral® (2009 - 2010 Season) in adults aged 18 to 60 years and over 60 years.
- Trial name
- NCT00929331
- Testing
- Fluviral®
- Where
- Canada
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Coronavirus Disease 2019
Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine
Popular topic：Clinical study of recombinant Novel Coronavirus vaccine (CHO cell) combined with influenza vaccine. Research purpose:Main purpose:To evaluate the immunogenicity of recombinant Novel Coronavirus vaccine (CHO cells)…
- Trial name
- NCT05107375
- Testing
- Tetravalent influenza virus lysis vaccine, Recombinant new coronavirus vaccine (CHO cell) group
- Where
- China
- Volunteers
- 299 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.